233 related articles for article (PubMed ID: 31867280)
1. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
2. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Cheng HL; Liu HS; Lin YJ; Chen HH; Hsu PY; Chang TY; Ho CL; Tzai TS; Chow NH
Br J Cancer; 2005 May; 92(10):1906-14. PubMed ID: 15870710
[TBL] [Abstract][Full Text] [Related]
5. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
Zou Y; Howell GM; Humphrey LE; Wang J; Brattain MG
PLoS One; 2013; 8(7):e69992. PubMed ID: 23922886
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
[TBL] [Abstract][Full Text] [Related]
7. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Thomas RM; Toney K; Fenoglio-Preiser C; Revelo-Penafiel MP; Hingorani SR; Tuveson DA; Waltz SE; Lowy AM
Cancer Res; 2007 Jul; 67(13):6075-82. PubMed ID: 17616662
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma.
Kim SA; Lee KH; Lee DH; Lee JK; Lim SC; Joo YE; Chung IJ; Noh MG; Yoon TM
Int J Oncol; 2019 Aug; 55(2):513-526. PubMed ID: 31268163
[TBL] [Abstract][Full Text] [Related]
9. Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.
Liu YZ; Han DT; Shi DR; Hong B; Qian Y; Wu ZG; Yao SH; Tang TM; Wang MH; Xu XM; Yao HP
World J Gastrointest Oncol; 2020 Nov; 12(11):1216-1236. PubMed ID: 33250957
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor.
Zou HY; Li Q; Lee JH; Arango ME; Burgess K; Qiu M; Engstrom LD; Yamazaki S; Parker M; Timofeevski S; Cui JJ; McTigue M; Los G; Bender SL; Smeal T; Christensen JG
Mol Cancer Ther; 2012 Apr; 11(4):1036-47. PubMed ID: 22389468
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais.
Lian S; Park JS; Xia Y; Nguyen TT; Joo YE; Kim KK; Kim HK; Jung YD
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27689991
[TBL] [Abstract][Full Text] [Related]
13. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
14. The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma.
Hayashi Y; Yamaguchi J; Kokuryo T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Nagino M
Anticancer Res; 2016 Dec; 36(12):6585-6592. PubMed ID: 27919987
[TBL] [Abstract][Full Text] [Related]
15. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
17. Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression.
Yang SY; Nguyen TT; Ung TT; Jung YD
Chonnam Med J; 2017 Sep; 53(3):178-186. PubMed ID: 29026705
[TBL] [Abstract][Full Text] [Related]
18. Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Int J Clin Exp Med; 2015; 8(11):20778-86. PubMed ID: 26885001
[TBL] [Abstract][Full Text] [Related]
19. Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer.
Yoon TM; Kim SA; Park YL; Lee KH; Sung MW; Lee JK; Lim SC; Chung IJ; Joo YE
Head Neck; 2013 Aug; 35(8):1106-13. PubMed ID: 22887469
[TBL] [Abstract][Full Text] [Related]
20. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
